



| CERTIFICATION OF ANALYSIS                   |                            |
|---|----------------------------|
| Product: Tirzepatide 18mg/2mL (2.4 mL Fill) | NDC: 84139-209-02          |
| Test Date: 13 Oct 2025                      | Batch No.: ProRx10082025@1 |
| Date of Mfg: 08 Oct 2025                    | Date of Exp: 08 Oct 2026   |

| Test                 | Specification                               | Result    |
|----------------------|---|-----------|
| Appearance           | Clear solution                              | Conforms  |
| Tirzepatide content  | 8.1 to 9.9 mg/mL                            | 8.9 mg/mL |
| Phenol content       | 4.5 to 5.5 mg/mL                            | 4.9 mg/mL |
| Sterility by ScanRDI | Conforms to sterility test as per USP <71>  | Pass      |
| Endotoxin            | Conforms to specifications as per USP <85>  | Pass      |
| Particulate          | Conforms to specifications as per USP <788> | Pass      |

**Results excluding appearance transcribed from third-party testing from Eagle Analytical.**

**Conclusion: Test results comply with product specifications**

|                               |                      |            |
|-------------------------------|----------------------|------------|
| Approved by:<br>Initials/Date | <i>Matthew Bross</i> | 2025-10-14 |
| Reviewed by:<br>Initials/Date | <i>Jessica Borie</i> | 2025-10-14 |

# Audit trail

## Details

FILE NAME COA-Tirzepatide 18mg/2mL ProRx10082025@1 - 14/10/2025, 08:08

STATUS ● Signed

STATUS TIMESTAMP 2025/10/14  
14:09:43 UTC

## Activity



cynthia@prorxpharma.com **sent** a signature request to:

- Matthew Bross (matthew@prorxpharma.com)
- Jessica Borie (jessica@prorxpharma.com)

2025/10/14  
12:08:57 UTC



**Signed** by Jessica Borie (jessica@prorxpharma.com)

2025/10/14  
14:09:43 UTC



**Signed** by Matthew Bross (matthew@prorxpharma.com)

2025/10/14  
14:06:54 UTC



This document has been signed by all signers and is **complete**

2025/10/14  
14:09:43 UTC

The email address indicated above for each signer may be associated with a Google account, and may either be the primary email address or secondary email address associated with that account.